biostudies-literatureWilshaw JBoehringer Ingelheim Animal Health GmBH755-770https://www.ebi.ac.uk/biostudies/studies/S-EPMC7995403biostudies-literatureUnknown35(2)<h4>Background</h4>Treatment is indicated in dogs with preclinical degenerative mitral valve disease (DMVD) and cardiomegaly (stage B2). This is best diagnosed using echocardiography; however, relying upon this limits access to accurate diagnosis.<h4>Objectives</h4>To evaluate whether cardiac biomarker concentrations can be used alongside other clinical data to identify stage B2 dogs.<h4>Animals</h4>Client-owned dogs (n = 1887) with preclinical DMVD prospectively sampled in Germany, the United Kingdom, and the United States.<h4>Methods</h4>Dogs that met inclusion criteria and were not receiving pimobendan (n = 1245) were used for model development. Explanatory (multivariable logistic regression) and predictive models were developed using clinical observations, biochemistry, and cardiac bioJournal of veterinary internal medicineAccuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease.PMC79954034192Boswood ADeinert MDutton EElliott JOyama MAWilshaw JGordon SGSchneider IWess GAbrantes RRosenthal SLDickson DBevilacqua LXia DfalseAccuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease.<h4>Background</h4>Treatment is indicated in dogs with preclinical degenerative mitral valve disease (DMVD) and cardiomegaly (stage B2). This is best diagnosed using echocardiography; however, relying upon this limits access to accurate diagnosis.<h4>Objectives</h4>To evaluate whether cardiac biomarker concentrations can be used alongside other clinical data to identify stage B2 dogs.<h4>Animals</h4>Client-owned dogs (n = 1887) with preclinical DMVD prospectively sampled in Germany, the United Kingdom, and the United States.<h4>Methods</h4>Dogs that met inclusion criteria and were not receiving pimobendan (n = 1245) were used for model development. Explanatory (multivariable logistic regression) and predictive models were developed using clinical observations, biochemistry, and cardiac bio2021-01-01T00:00:00Z2021 Mar2025-05-31T23:33:19.46Z2025-05-31T23:33:19.46ZS-EPMC79954033364584610.1111/jvim.16083